UNSPSC 51132204: Acetaminophen/aspirin

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN103. This VA Drug Class (CN103) classifies this compound as belonging to the group NON-OPIOID ANALGESICS.

UNSPSC 51132204 Acetaminophen/aspirin, a Commodity code, nominally covers over-the-counter pain relievers, but recent state and local solicitations using this code diverge significantly from that scope. The three recent opportunities indexed under the code actually procure naloxone and drug deactivation systems (Seminole County, Florida), direct-to-manufacturer pharmacy prescription programs (Texas HHS), and generic multi-source pharmaceuticals and OTC products through cooperative purchasing (Minnesota). The mismatch suggests that state and local procurement systems are applying this code as a catch-all for pharmaceutical and OTC procurement rather than restricting it to acetaminophen and aspirin products. State agencies, counties, and multistate cooperative purchasing vehicles are the primary issuing bodies, with Texas Health and Human Services, Minnesota Department of Administration (via MMCAP), and Seminole County representing this mix.

Recent activity spans Texas, Minnesota (with participation from Oregon through MMCAP), and Florida. The Seminole County IFB for naloxone and drug deactivation systems (1,900 units of naloxone and 800 deactivation systems annually, due July 26, 2023) represents direct county health procurement. The Texas HHS Commission's RFI (HHS0017013, posted April 3, 2026) seeks vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, functioning as early market intelligence before a formal RFP. The Minnesota MMCAP RFP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products represents multistate cooperative purchasing, requiring manufacturers to work through three authorized wholesalers (Cencora, Cardinal Health, Morris & Dickson) and imposing a 3 percent administrative fee and performance penalties ranging from $200 to $1,500 per violation. The code shows limited relevant activity when filtered to actual acetaminophen and aspirin procurement; opportunities are being tagged under this code to represent broader pharmaceutical and OTC supply.